ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.96
0.17%
US Tech 100
20,631.20
0.10%
S&P 500
6,045.31
-0.03%
US Dollar vs CAD
1.40566
0.08%
Bitcoin
95,047.90
-0.85%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Genfit (GNFT)

  7. Genfit (GNFT) News

GNFT

Genfit (GNFT)

Genfit
Date:
Sort by:
 Showing the most relevant articles for your search:EU:GNFT
DateTimeSourceHeadlineSymbolCompany
11/13/20243:10PMGlobeNewswire Inc.GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024EU:GNFTGenfit
11/07/20243:10PMGlobeNewswire Inc.GENFIT Reports Third Quarter 2024 Financial InformationEU:GNFTGenfit
09/23/202412:30AMGlobeNewswire Inc.GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated ApprovalEU:GNFTGenfit
09/19/20243:10PMGlobeNewswire Inc.GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate UpdateEU:GNFTGenfit
07/26/20246:45AMGlobeNewswire Inc.GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary CholangitisEU:GNFTGenfit
06/17/20243:10PMGlobeNewswire Inc.GENFIT : Les nouvelles recommandations de pratique clinique de l'EASL-EASD-EASO pour la MASLD incluent NIS2+® comme outil-clé pour la détection de la MASH à risque  EU:GNFTGenfit
06/17/20243:10PMGlobeNewswire Inc.GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASHEU:GNFTGenfit
06/17/20243:10PMGlobeNewswire Inc.GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASHEU:GNFTGenfit
06/10/20244:22PMGlobeNewswire Inc.GENFIT : Étape historique franchie avec l'approbation accélérée d'Iqirvo® d’Ipsen dans la Cholangite Biliaire Primitive par la FDA américaineEU:GNFTGenfit
06/10/20244:22PMGlobeNewswire Inc.GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary CholangitisEU:GNFTGenfit
06/10/20244:22PMGlobeNewswire Inc.GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary CholangitisEU:GNFTGenfit
05/29/20243:10PMGlobeNewswire Inc.GENFIT présentera ses dernières avancées dans l'ACLF à l'EASL Congress™ 2024  EU:GNFTGenfit
05/29/20243:10PMGlobeNewswire Inc.GENFIT to Present Latest ACLF Research at EASL Congress™ 2024EU:GNFTGenfit
05/29/20243:10PMGlobeNewswire Inc.GENFIT to Present Latest ACLF Research at EASL Congress™ 2024EU:GNFTGenfit
05/22/202411:05AMGlobeNewswire Inc.GENFIT: May 22, 2024 Combined Shareholders Meeting ResultsEU:GNFTGenfit
05/22/202411:05AMGlobeNewswire Inc.GENFIT : Résultats de l’Assemblée Générale Mixte du 22 mai 2024EU:GNFTGenfit
05/22/202411:05AMGlobeNewswire Inc.GENFIT: May 22, 2024 Combined Shareholders Meeting ResultsEU:GNFTGenfit
05/14/20243:10PMGlobeNewswire Inc.GENFIT : Information financière du premier trimestre 2024EU:GNFTGenfit
05/14/20243:10PMGlobeNewswire Inc.GENFIT Reports First Quarter 2024 Financial InformationEU:GNFTGenfit
05/14/20243:10PMGlobeNewswire Inc.GENFIT Reports First Quarter 2024 Financial InformationEU:GNFTGenfit
04/25/20243:10PMGlobeNewswire Inc.GENFIT : Publication du rapport de performance extra-financière 2024 (exercice 2023)EU:GNFTGenfit
04/25/20243:10PMGlobeNewswire Inc.GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)EU:GNFTGenfit
04/25/20243:10PMGlobeNewswire Inc.GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)EU:GNFTGenfit
04/15/20243:10PMGlobeNewswire Inc.GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsEU:GNFTGenfit
04/15/20243:10PMGlobeNewswire Inc.GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires EU:GNFTGenfit
04/15/20243:10PMGlobeNewswire Inc.GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsEU:GNFTGenfit
04/05/20241:00PMGlobeNewswire Inc.GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FEU:GNFTGenfit
04/05/20241:00PMGlobeNewswire Inc.GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FEU:GNFTGenfit
04/05/20241:00PMGlobeNewswire Inc.GENFIT : Mise à disposition du Document d’Enregistrement Universel 2023 et du Rapport Annuel Form 20-F 2023EU:GNFTGenfit
04/04/20243:10PMGlobeNewswire Inc.GENFIT : Résultats financiers annuels 2023 et point sur les activités de la SociétéEU:GNFTGenfit
 Showing the most relevant articles for your search:EU:GNFT

Your Recent History

USOTC
HMBL
HUMBL (PK)
USOTC
RDAR
Raadr (PK)
USOTC
BIEL
Bioelectronics (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
TPTW
TPT Global Tech (CE)
USOTC
IFUS
Impact Fusion (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
FNMA
Fannie Mae (QB)
USOTC
CBRF
CyberFuels (PK)
USOTC
RNVA
Rennova Health (CE)
USOTC
MONI
Moon Equity (PK)
USOTC
AZRH
Azure (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
NBRI
North Bay Resources (PK)
USOTC
ABQQ
AB (PK)
USOTC
ASII
Accredited Solutions (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved